Instil Bio (TIL) Competitors $36.56 -1.00 (-2.66%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$36.56 0.00 (0.00%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TIL vs. AVBP, NTLA, CRON, REPL, IMTX, GYRE, DAWN, VIR, AVXL, and ABUSShould you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include ArriVent BioPharma (AVBP), Intellia Therapeutics (NTLA), Cronos Group (CRON), Replimune Group (REPL), Immatics (IMTX), Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Instil Bio vs. Its Competitors ArriVent BioPharma Intellia Therapeutics Cronos Group Replimune Group Immatics Gyre Therapeutics Day One Biopharmaceuticals Vir Biotechnology Anavex Life Sciences Arbutus Biopharma Instil Bio (NASDAQ:TIL) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk. Which has more volatility & risk, TIL or AVBP? Instil Bio has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Does the media prefer TIL or AVBP? In the previous week, ArriVent BioPharma had 2 more articles in the media than Instil Bio. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for Instil Bio. ArriVent BioPharma's average media sentiment score of 1.12 beat Instil Bio's score of 0.30 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Instil Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, TIL or AVBP? ArriVent BioPharma is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInstil BioN/AN/A-$156.09M-$11.97-3.05ArriVent BioPharmaN/AN/A-$69.33M-$3.77-6.18 Is TIL or AVBP more profitable? Instil Bio's return on equity of -37.44% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Instil BioN/A -37.44% -25.08% ArriVent BioPharma N/A -43.89%-29.67% Do analysts rate TIL or AVBP? Instil Bio currently has a consensus price target of $119.00, suggesting a potential upside of 225.49%. ArriVent BioPharma has a consensus price target of $39.29, suggesting a potential upside of 68.75%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders & institutionals believe in TIL or AVBP? 60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 47.2% of Instil Bio shares are owned by company insiders. Comparatively, 18.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer TIL or AVBP? Instil Bio received 81 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 95.83% of users gave ArriVent BioPharma an outperform vote while only 50.49% of users gave Instil Bio an outperform vote. CompanyUnderperformOutperformInstil BioOutperform Votes10450.49% Underperform Votes10249.51% ArriVent BioPharmaOutperform Votes2395.83% Underperform Votes14.17% SummaryInstil Bio beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks. Get Instil Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TIL vs. The Competition Export to ExcelMetricInstil BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$246.39M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-3.1633.3227.1320.06Price / SalesN/A469.84412.28157.10Price / CashN/A168.6838.2534.64Price / Book1.053.457.064.70Net Income-$156.09M-$72.35M$3.23B$247.88M7 Day Performance20.54%6.23%2.86%2.63%1 Month Performance167.25%16.53%9.05%6.36%1 Year Performance239.78%-16.90%31.39%14.05% Instil Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TILInstil Bio2.6702 of 5 stars$36.56-2.7%$119.00+225.5%+237.3%$246.39MN/A-3.16410Short Interest ↑High Trading VolumeAVBPArriVent BioPharma1.4586 of 5 stars$22.00+3.5%$39.29+78.6%+24.4%$752.69MN/A-5.8440Positive NewsHigh Trading VolumeNTLAIntellia Therapeutics4.5892 of 5 stars$7.16+4.2%$36.75+413.3%-64.8%$741.65M$45.57M-1.32600Analyst RevisionGap UpHigh Trading VolumeCRONCronos Group1.9294 of 5 stars$1.92-3.0%N/A-21.0%$739.98M$124.59M-14.77450Positive NewsREPLReplimune Group4.509 of 5 stars$9.57+6.6%$19.75+106.4%+8.7%$737.72MN/A-3.12210Positive NewsHigh Trading VolumeIMTXImmatics2.6803 of 5 stars$6.01+11.5%$14.67+144.0%-55.1%$730.52M$144.15M-9.11260Analyst RevisionGap UpHigh Trading VolumeGYREGyre Therapeutics0.367 of 5 stars$7.68-15.3%N/A-21.8%$720.06M$100.64M384.0040Short Interest ↓High Trading VolumeDAWNDay One Biopharmaceuticals1.7291 of 5 stars$7.01+9.9%$30.57+336.1%-46.2%$710.55M$161.92M-6.8160VIRVir Biotechnology3.0685 of 5 stars$5.07+2.6%$32.86+548.1%-50.6%$700.87M$14.30M-1.29580Positive NewsAVXLAnavex Life Sciences3.9304 of 5 stars$7.56+0.4%$44.00+482.0%+121.6%$645.41MN/A-13.7540Positive NewsABUSArbutus Biopharma2.2499 of 5 stars$3.36flat$5.50+63.7%+10.1%$643.53M$6.40M-7.8190Positive News Related Companies and Tools Related Companies AVBP Competitors NTLA Competitors CRON Competitors REPL Competitors IMTX Competitors GYRE Competitors DAWN Competitors VIR Competitors AVXL Competitors ABUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TIL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
